Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: A pilot study

Urologia Internationalis

Volumn 76, Issue 2, 2006, Pages 106-111

  Gacci, Mauro ^a   Bartoletti, Riccardo ^a   Cai, Tommaso ^a   Nerozzi, Stefano ^b   Pinzi, Novelle ^c   Repetti, Fabrizio ^c   Viggiani, Fabrizio ^d   Ghezzi, Paolo ^e   Nesi, Gabriella ^a   Carini, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Hospital of Pistoia   (Italy)

^c Hospital of Lucca   (Italy)

^d Hospital of Grosseto   (Italy)

^e Hospital of Arezzo   (Italy)

Author keywords

Bacille Calmette Gu rin; Bladder tumor; Gemcitabine; Transitional cell carcinoma

Indexed keywords

BCG VACCINE; GEMCITABINE;

ADULT; AGED; ARTICLE; ASTHENIA; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEMATURIA; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; TREATMENT FAILURE; URINARY BLADDER NEOPLASMS;

EID: 33745049728     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090870     Document Type: Article

References (29)

1. Soloway MS, Sofer M, Vaidya A: Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002;167:1573-1583.
2. Gottengo B: T1G3 Bladder cancer: conservative management or cystectomy? Eur Urol 2004;45:339-400.
3. Thalmann G, Markwalder R, Shahin O, Burkhard F, Hochreiter W, Studer U: Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 2004;172:70-75.
4. Patard J, Moudouni S, Saint F, Rioux-Leclercq N, Manunta A, Guy L, Ballanger P, Lanson Y, Hajri M, Irani J, Guille F, Beurton D, Lobel B: Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology 2001;58:551-556.
5. Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN: Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacilli Calmette-Guérin: 18-year experience. Urology 2002;59:227-231.
6. Bohle A, Bock PR: Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-687.
7. Saint F, Salomon L, Quintela R, Cicco A, Abbou CC, Chopin DK: Classification, favorable characteristics, prevention and treatment of adverse side effects associated with bacillus Calmette-Guérin in the treatment of superficial bladder cancer. Ann Urol 2002;36:120-131.
8. Rintala E, Jauhiainen K, Kaasinen E, Nurmi M, Alfthan O: Alternating mitomycin C and bacillus Calmette-Guérin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group. J Urol 1996;156:56-60.
9. Bilen CY, Ozen H, Aki FT, Aygun C, Ekici S, Kendi S: Clinical experience with BCG alone versus BCG plus epirubicin. Int J Urol 2000;7:206-209.
10. Steinberg G, Bahnson R, Brosman S, Middelton R, Wajsman Z, Wehle M: Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000;1633:761-767.
11. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
12. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
13. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N: Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997;15:3441-3445.
14. Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WD, Dalbagni G: Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 1999;5:2629-2637.
15. Herr HW, Dalbagni G: Defining bacillus Calmette-Guérin refractory superficial bladder tumors. J Urol 2003;169:1706-1708.
16. Pagano F, Garbeglio A, Milani C, Bassi P, Pegoraro V: Prognosis of bladder cancer. I. Risk factors in superficial transitional cell carcinoma. Eur Urol 1987;13:145-151.
17. Palou J, Carcas A, Segarra J, Duque B, Salvador J, Garcia-Ribas I, Villavicencio H: Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. J Urol 2004;172:485-488.
18. Jakse G, Algaba F, Malmstrom PU, Oosterlinck W: A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 2004;45:539-546.
19. Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;23:1435-1448.
20. Jakse G, Loidl W, Seeber G, Hofstadter F: Stage T1 grade 3 transitional cell carcinoma of the bladder: an unfavourable tumor? J Urol 1987;137:39-43.
21. Bracken RB, McDonald MW, Johnson DE: Cystectomy for superficial bladder cancer. Urology 1981;18:459-463.
22. Peyromaure M, Zerbib M: T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int 2004;93:60-63.
23. Patard J, Moudouni S, Saint F, Rioux-Leclercq N, Manunta A, Guy L, Ballanger P, Lanson Y, Hajri M, Irani J, Guille F, Beurton D, Lobel B, Bernard Lobel and the members of the Groupe Necker: Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology 2001;58:551-556.
24. Herr HW: Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997;80:762-765.
25. Baniel J, Grauss D, Engelstein D, Sella A: Intravesical bacillus Calmette-Guérin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 1998;52:785-789.
26. Bretton PR, Herr HW, Kimmel M, Whitmore WF Jr, Laudone V, Oettgen HF, Fair WR: The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guérin. J Urol 1990;143:710-713.
27. Joudi FN, O'Donnell MA: Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures. Curr Opin Urol 2004;14:271-275.
28. Laufer M, Ramalingam S, Schoenberg MP, Haisfield-Wolf ME, Zuhowski EG, Trueheart IN, Eisenberger MA, Nativ O, Egorin MJ: Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 2003;21:697-703.
29. Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, Donat MS, Herr HW, Sogani P, dePalma D, Bajorin D: Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 2002;20:3193-3198.